Zhang Hefeng, Liu Shihu, Zhang Jinzi, Wang Yongjie
Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
PLoS One. 2024 Dec 9;19(12):e0314228. doi: 10.1371/journal.pone.0314228. eCollection 2024.
Non-small cell lung cancer (NSCLC) has a high incidence, with most patients diagnosed beyond the optimal surgical window. Improving survival rates is critical to reducing lung cancer mortality, and identifying immune checkpoints is vital for prognosis stratification.
To investigate the expression of CD47 in NSCLC and its relationship with tumor-associated macrophage infiltration.
A retrospective analysis was conducted on 50 NSCLC patients treated between January 2014 and June 2018. Immunohistochemistry and confocal microscopy assessed CD47 expression in tumor and adjacent tissues, while immunofluorescence evaluated CD47 on tumor-infiltrating T lymphocytes. Kaplan-Meier survival analysis and Cox regression identified prognostic factors, and PLA technology examined CD47's interaction with VEGFR and CD36.
CD47 positivity in tumor tissues (52%) was significantly higher than in adjacent tissues (20%) (P<0.001), with expression localized to the cell membrane. CD47 expression correlated with lymph node metastasis, clinical stage, and differentiation (P<0.05) and was identified as an independent risk factor for poor prognosis. TAM infiltration was greater in CD47-positive patients and correlated with shorter survival (P<0.05). PLA showed stronger CD47+VEGFR interactions than CD47+CD36.
CD47 positivity correlates with poor prognosis and increased TAM infiltration, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC.
非小细胞肺癌（NSCLC）发病率高，大多数患者在最佳手术窗口期后才被诊断出来。提高生存率对于降低肺癌死亡率至关重要，而识别免疫检查点对于预后分层至关重要。
研究CD47在NSCLC中的表达及其与肿瘤相关巨噬细胞浸润的关系。
对2014年1月至2018年6月期间接受治疗的50例NSCLC患者进行回顾性分析。免疫组织化学和共聚焦显微镜评估肿瘤组织和癌旁组织中CD47的表达，免疫荧光评估肿瘤浸润性T淋巴细胞上的CD47。Kaplan-Meier生存分析和Cox回归确定预后因素，PLA技术检测CD47与VEGFR和CD36的相互作用。
肿瘤组织中CD47阳性率（52%）显著高于癌旁组织（20%）（P<0.001），表达定位于细胞膜。CD47表达与淋巴结转移、临床分期和分化相关（P<0.05），并被确定为预后不良的独立危险因素。CD47阳性患者的TAM浸润更多，且与较短生存期相关（P<0.05）。PLA显示CD47+VEGFR的相互作用比CD47+CD36更强。
CD47阳性与预后不良和TAM浸润增加相关，突出了其作为NSCLC预后生物标志物和治疗靶点的潜力。
